{
  "docId": "019de074-71be-772a-8bed-f9d5eaece76b",
  "docSlug": "e4f10758c80bf7a23f09bd201ccd4281",
  "documentTitle": "Alkermes | Investor Presentation Deck | 32 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 32,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide outlines a two-stage clinical development process with specific objectives and assessment criteria for each phase.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-71be-772a-8bed-f9d5eaece76b/22",
  "deckHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b",
  "deckJsonHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b.json",
  "deckAnchorHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.43,
        "x": 0.53,
        "y": 0.32
      },
      "kind": "list",
      "text": "Objective: Early POC data + dose range estimation for phase 2 in lead indications. Key Assessments: EEG-based maintenance of wakefulness test, Drug exposure (PK), Evaluate safety and tolerability. Study initiation expected H1 2023.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1600813b-50ed-4891-92b9-3a21c3db8029",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.43,
        "x": 0.06,
        "y": 0.32
      },
      "kind": "list",
      "text": "Objective: Measure and model pharmacokinetics (PK)/pharmacodynamics (PD) and evaluate safety and tolerability of single and multiple ascending doses. Key Assessments: Drug exposure (PK), Evaluate safety and tolerability. Exploratory assessment: qEEG trends.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d4ef197-9355-4fe2-87d9-391f90621d99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Phase 1b Proof-of-Concept (POC) Study",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8145082a-75c8-44fb-974c-ff6dcf0c633d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Phase 1 First-in-Human (FIH) Studies",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd897b5f-b3f2-4551-a6ff-2c4213e3f2ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "EEG: electroencephalogram; qEEG: quantitative electroencephalogram",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b6b0c3f-7fdf-40fa-abff-2f48a6abb200",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ALKS 2680 Clinical Development Plan Targeting Clinical Proof-of-Concept Data by Year-End 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fe1b530-c2a9-4ed2-a323-71e22e7df0b2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 22,
      "from": 21,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "07dbb454-3026-43e8-a816-ba3cbb6f21ed",
      "evidence": "ALKS 2680 Clinical Development Plan",
      "position": 2,
      "objective": "why ALKS 2680 is a promising opportunity",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}